Trials / Completed
CompletedNCT02944604
The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 240 (actual)
- Sponsor
- Peking University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer who were treated with intensive chemotherapy for prevention of neutrophil reduction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PEG-rhG-CSF |
Timeline
- Start date
- 2016-09-08
- Primary completion
- 2017-09-29
- Completion
- 2017-09-30
- First posted
- 2016-10-26
- Last updated
- 2019-01-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02944604. Inclusion in this directory is not an endorsement.